Insmed Inc (INSM)vsZevra Therapeutics Inc. (ZVRA)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
ZVRA
Zevra Therapeutics Inc.
$9.13
-0.22%
HEALTHCARE · Cap: $537.21M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 470% more annual revenue ($606.42M vs $106.47M). ZVRA leads profitability with a 78.2% profit margin vs -2.1%. INSM appears more attractively valued with a PEG of 1.09. ZVRA earns a higher WallStSmart Score of 62/100 (C+).
INSM
Hold39
out of 100
Grade: F
ZVRA
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
+7.6%
Fair Value
$9.18
Current Price
$9.13
$0.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Attractively priced relative to earnings
Every $100 of equity generates 86 in profit
Keeps 78 of every $100 in revenue as profit
Strong operational efficiency at 27.3%
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
1.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : ZVRA
The strongest argument for ZVRA centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 78.2% and operating margin at 27.3%.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : ZVRA
The primary concerns for ZVRA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while ZVRA is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
ZVRA is growing revenue faster at 1.8% — sustainability is the question.
ZVRA generates stronger free cash flow (5M), providing more financial flexibility.
Bottom Line
ZVRA scores higher overall (62/100 vs 39/100), backed by strong 78.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?